TehOChris
2021-08-11
Nivavax over both
Why Shares of BioNTech Were Falling Today<blockquote>为什么 BioNTech 股价今天下跌</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":892188536,"tweetId":"892188536","gmtCreate":1628643875025,"gmtModify":1633745474676,"author":{"id":3582343092162434,"idStr":"3582343092162434","authorId":3582343092162434,"authorIdStr":"3582343092162434","name":"TehOChris","avatar":"https://static.tigerbbs.com/e30ddf46446866173986a5c85e5f4e88","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":18,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Nivavax over both</p></body></html>","htmlText":"<html><head></head><body><p>Nivavax over both</p></body></html>","text":"Nivavax over both","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/892188536","repostId":1134501157,"repostType":4,"repost":{"id":"1134501157","kind":"news","pubTimestamp":1628642716,"share":"https://www.laohunote.com/m/news/1134501157?lang=zh_CN&edition=full","pubTime":"2021-08-11 08:45","market":"us","language":"en","title":"Why Shares of BioNTech Were Falling Today<blockquote>为什么 BioNTech 股价今天下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1134501157","media":"The Motley Fool","summary":"Researchers might have found some difference between mRNA vaccine makers.\nWhat happened\nShares of Bi","content":"<p><i>Researchers might have found some difference between mRNA vaccine makers.</i></p><p><blockquote><i>研究人员可能已经发现了mRNA疫苗制造商之间的一些差异。</i></blockquote></p><p> <h3><b>What happened</b></h3> Shares of <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> were down nearly 7% today after two studies of more than 50,000 patients in the Mayo Clinic Health System showed rival <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s vaccine might be more effective against the troublesome delta variant of the SARS-CoV-2 coronavirus.</p><p><blockquote><h3><b>发生了什么事</b></h3>股份<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>梅奥诊所医疗系统对 50,000 多名患者进行的两项研究显示竞争对手，今天下跌了近 7%<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>的疫苗可能对 SARS-CoV-2 冠状病毒的麻烦德尔塔变异毒株更有效。</blockquote></p><p> The effectiveness of BioNTech's vaccine, developed with <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, was only 42% during July, according to the study, compared to 76% for Moderna. The numbers were calculated at a time that delta has become the dominant strain infecting Americans. A second study showed nursing home residents generated stronger immune responses after the Moderna vaccine than after BioNTech's.</p><p><blockquote>BioNTech 疫苗的有效性<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>根据这项研究，7 月份的这一比例仅为 42%，而 Moderna 的这一比例为 76%。这些数字是在德尔塔已经成为感染美国人的主要毒株的时候计算的。第二项研究表明，与 BioNTech 疫苗相比，养老院居民在接种 Moderna 疫苗后产生了更强的免疫反应。</blockquote></p><p> <h3><b>So what</b></h3> With so many Americans already vaccinated, the study won't have as much impact as it might have had if it came out earlier this year. Still, it might sway those who remain unvaccinated to seek out the Moderna jab over BioNTech's. There are still more than 700,000 vaccinations happening per day, enough to move the needle financially.</p><p><blockquote><h3><b>那又怎样</b></h3>由于这么多美国人已经接种了疫苗，这项研究不会像今年早些时候发表那样产生那么大的影响。尽管如此，这可能会影响那些仍未接种疫苗的人寻求 Moderna 疫苗而不是 BioNTech 疫苗。每天仍有超过 70 万次疫苗接种，足以在经济上推动疫苗接种。</blockquote></p><p> <h3><b>Now what</b></h3> It may also impact the demand for boosters. Despite the hesitancy of the Food and Drug Administration and the Centers for Disease Control and Prevention, there is little doubt that additional shots to maintain immunity will be necessary. It's been reported that the agencies could authorize them for the 7 million immunocompromised Americans as soon as this month.</p><p><blockquote><h3><b>现在呢</b></h3>它也可能影响对助推器的需求。尽管美国食品药品监督管理局和疾病控制与预防中心犹豫不决，但毫无疑问，需要额外注射以维持免疫力。据报道，这些机构最早可能在本月批准700万免疫功能低下的美国人使用这些药物。</blockquote></p><p> The move today couldn't have been all about the data, though. Moderna shares fell almost 6%. Investors will need to watch for any updates as the studies go to peer review. As it stands, Moderna and BioNTech expect $20 billion and $18.6 billion, respectively, in vaccine revenuethis year.</p><p><blockquote>不过，今天的举动不可能完全是为了数据。Moderna股价下跌近6%。随着这些研究进入同行评审，投资者需要关注任何更新。目前，Moderna 和 BioNTech 预计今年的疫苗收入分别为 200 亿美元和 186 亿美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Shares of BioNTech Were Falling Today<blockquote>为什么 BioNTech 股价今天下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Shares of BioNTech Were Falling Today<blockquote>为什么 BioNTech 股价今天下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-08-11 08:45</span>\n</p>\n</h4>\n</header>\n<article>\n<p><i>Researchers might have found some difference between mRNA vaccine makers.</i></p><p><blockquote><i>研究人员可能已经发现了mRNA疫苗制造商之间的一些差异。</i></blockquote></p><p> <h3><b>What happened</b></h3> Shares of <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> were down nearly 7% today after two studies of more than 50,000 patients in the Mayo Clinic Health System showed rival <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s vaccine might be more effective against the troublesome delta variant of the SARS-CoV-2 coronavirus.</p><p><blockquote><h3><b>发生了什么事</b></h3>股份<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>梅奥诊所医疗系统对 50,000 多名患者进行的两项研究显示竞争对手，今天下跌了近 7%<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>的疫苗可能对 SARS-CoV-2 冠状病毒的麻烦德尔塔变异毒株更有效。</blockquote></p><p> The effectiveness of BioNTech's vaccine, developed with <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, was only 42% during July, according to the study, compared to 76% for Moderna. The numbers were calculated at a time that delta has become the dominant strain infecting Americans. A second study showed nursing home residents generated stronger immune responses after the Moderna vaccine than after BioNTech's.</p><p><blockquote>BioNTech 疫苗的有效性<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>根据这项研究，7 月份的这一比例仅为 42%，而 Moderna 的这一比例为 76%。这些数字是在德尔塔已经成为感染美国人的主要毒株的时候计算的。第二项研究表明，与 BioNTech 疫苗相比，养老院居民在接种 Moderna 疫苗后产生了更强的免疫反应。</blockquote></p><p> <h3><b>So what</b></h3> With so many Americans already vaccinated, the study won't have as much impact as it might have had if it came out earlier this year. Still, it might sway those who remain unvaccinated to seek out the Moderna jab over BioNTech's. There are still more than 700,000 vaccinations happening per day, enough to move the needle financially.</p><p><blockquote><h3><b>那又怎样</b></h3>由于这么多美国人已经接种了疫苗，这项研究不会像今年早些时候发表那样产生那么大的影响。尽管如此，这可能会影响那些仍未接种疫苗的人寻求 Moderna 疫苗而不是 BioNTech 疫苗。每天仍有超过 70 万次疫苗接种，足以在经济上推动疫苗接种。</blockquote></p><p> <h3><b>Now what</b></h3> It may also impact the demand for boosters. Despite the hesitancy of the Food and Drug Administration and the Centers for Disease Control and Prevention, there is little doubt that additional shots to maintain immunity will be necessary. It's been reported that the agencies could authorize them for the 7 million immunocompromised Americans as soon as this month.</p><p><blockquote><h3><b>现在呢</b></h3>它也可能影响对助推器的需求。尽管美国食品药品监督管理局和疾病控制与预防中心犹豫不决，但毫无疑问，需要额外注射以维持免疫力。据报道，这些机构最早可能在本月批准700万免疫功能低下的美国人使用这些药物。</blockquote></p><p> The move today couldn't have been all about the data, though. Moderna shares fell almost 6%. Investors will need to watch for any updates as the studies go to peer review. As it stands, Moderna and BioNTech expect $20 billion and $18.6 billion, respectively, in vaccine revenuethis year.</p><p><blockquote>不过，今天的举动不可能完全是为了数据。Moderna股价下跌近6%。随着这些研究进入同行评审，投资者需要关注任何更新。目前，Moderna 和 BioNTech 预计今年的疫苗收入分别为 200 亿美元和 186 亿美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/10/why-shares-of-biontech-are-falling-today/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/10/why-shares-of-biontech-are-falling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134501157","content_text":"Researchers might have found some difference between mRNA vaccine makers.\nWhat happened\nShares of BioNTech SE were down nearly 7% today after two studies of more than 50,000 patients in the Mayo Clinic Health System showed rival Moderna, Inc.'s vaccine might be more effective against the troublesome delta variant of the SARS-CoV-2 coronavirus.\nThe effectiveness of BioNTech's vaccine, developed with Pfizer, was only 42% during July, according to the study, compared to 76% for Moderna. The numbers were calculated at a time that delta has become the dominant strain infecting Americans. A second study showed nursing home residents generated stronger immune responses after the Moderna vaccine than after BioNTech's.\nSo what\nWith so many Americans already vaccinated, the study won't have as much impact as it might have had if it came out earlier this year. Still, it might sway those who remain unvaccinated to seek out the Moderna jab over BioNTech's. There are still more than 700,000 vaccinations happening per day, enough to move the needle financially.\nNow what\nIt may also impact the demand for boosters. Despite the hesitancy of the Food and Drug Administration and the Centers for Disease Control and Prevention, there is little doubt that additional shots to maintain immunity will be necessary. It's been reported that the agencies could authorize them for the 7 million immunocompromised Americans as soon as this month.\nThe move today couldn't have been all about the data, though. Moderna shares fell almost 6%. Investors will need to watch for any updates as the studies go to peer review. As it stands, Moderna and BioNTech expect $20 billion and $18.6 billion, respectively, in vaccine revenuethis year.","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":606,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":15,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/892188536"}
精彩评论